Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05229445 · ClinicalTrials.gov registry record · NA
A Continuous Glucose Monitor Based Insulin Bolus Calculator
A NA study of Diabetes Mellitus, Type 2 and Diabetes Mellitus, Type 1, sponsored by Welldoc.
- Completed
- Registry status
- NA
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT05229445: Completed NA study of Diabetes Mellitus, Type 2 and Diabetes Mellitus, Type 1, sponsored by Welldoc.
NCT05229445 is a NA study of Diabetes Mellitus, Type 2 and Diabetes Mellitus, Type 1 that has completed, run by Welldoc. The registered enrollment target is 27 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05229445, a NA study of Diabetes Mellitus, Type 2 and Diabetes Mellitus, Type 1, has completed, sponsored by Welldoc.
- COMPLETED
- Registry status
- NA
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
This study examines the safety of an app-based insulin bolus calculator that utilizes glucose values from a continuous glucose monitor
Primary Outcome
time in range using the calculator app will be non-inferior to baseline time in range
Conditions Studied
Interventions
- DEVICE continuous glucose monitor based insulin bolus calculator
Study Locations (1)
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2022-07-05 |
| Est. Completion | 2022-09-28 |
| Phase | NA |
What the finished NCT05229445 record still lists
NCT05229445 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 1 intervention - of which continuous glucose monitor based insulin bolus calculator is the first listed.
NCT05229445 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT05229445 about?
NCT05229445 is a clinical study titled "A Continuous Glucose Monitor Based Insulin Bolus Calculator". This study examines the safety of an app-based insulin bolus calculator that utilizes glucose values from a continuous glucose monitor
What is the current status of trial NCT05229445?
This trial is currently completed. It is a NA study. The enrollment target is 27 participants. The study started on 2022-07-05. Estimated completion is 2022-09-28.
What conditions does trial NCT05229445 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1.
What interventions are being tested in trial NCT05229445?
The interventions under investigation include: continuous glucose monitor based insulin bolus calculator (DEVICE).
Who is sponsoring clinical trial NCT05229445?
This trial is sponsored by Welldoc, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05229445 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05229445's enrollment target sits among peer trials
27 303rd of 348 higher than 44 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
RECRUITING · NA
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Trial to Assess Continuous Glucose Monitoring in Asian Americans With Type 2 Diabetes
RECRUITING · NA
-
Efficacy of mHealth Apps for Health in a Low-income, Type II Diabetic, Hispanic Population
RECRUITING · NA
-
Phenotyping Genetic Risk for Type 2 Diabetes
RECRUITING · NA
-
Diabetes Learning in Virtual Environments Just in Time for Community Reentry
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI